Thursday, 5 November 2026European Markets

AURES TECHNOLOGIES Stock Is 22% Up In The Last 10 Sessions

Loading stream...

(vianews) - shares of aures technologies (cac 40: aurs.pa) rose by a staggering 22.76% in 10 sessions from €5.8 to €7.12 at 14:41 est on friday, after four sequential sessions in a row of losses. cac 40 is rising 0.7% to €7,433.49, following the last session's upward trend.

about aures technologies

aures technologies s.a. engages in manufacture of hardware and digital application solutions for point of sale and retail industry. the company provides all-in-one touch screen terminals, pos systems, and retail solutions; kiosk products; pos and mobile tablets; touchscreen panels; pos thermal receipt printers; complementary screens, displays, and monitors; and a range of accessories, such as barcode scanners, specific readers for magnetic cards, biometric readers, and rfid readers. it also offers consulting, staging, installation, decommissioning, asset tracking, real time pos monitoring, and onsite support services. the company offers its products for food and non-food stores, shops, retail outlets, superstores and supermarkets, catering and hospitality businesses, snacking and takeaway outlets, leisure and sport venues, etc. it markets its products through a network of distributors, resellers, agents, and partners in france, the united kingdom, germany, australia, the united states, and internationally. the company was incorporated in 1989 and is headquartered in lisses, france.

earnings per share

as for profitability, aures technologies has a trailing twelve months eps of €0.37.

pe ratio

aures technologies has a trailing twelve months price to earnings ratio of 19.45. meaning, the purchaser of the share is investing €19.45 for every euro of annual earnings.

volume

today's last reported volume for aures technologies is 2817 which is 51.99% below its average volume of 1708.

more news about aures technologies (aurs.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com